Aclaris Therapeutics (ACRS) Tops Q1 EPS by 9c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.31), $0.09 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• DeFi Technologies Inc. (DEFT) Reports Q2 Loss of $0.04
• RCM Technologies (RCMT) Tops Q2 EPS by 17c